Cohance Lifesciences Limited CC-Sep23.pdf · 2023-11-09
So, if you could spell out some more details on this Agribusiness. You did say that there's some de- stocking, but your interaction with the clients turning out to be pretty good. So, in terms of, at -least, the custom synthesis part, how's the development, whether you would be adding new technologies there, and did Suven had a concentrated portfolio, and post the merger, we want to diversify. So, any broad colour in terms of new technologies that you would be looking at would be helpful.
And in terms of capital allocation going ahead, is there a certain bias on the part of the management that would like to put more capital towards CDMO pharma, less towards agri, any thought process?